冠心静胶囊治疗慢性稳定型心绞痛:随机对照试验方案
本研究为多中心、盲法、随机对照试验,计划纳入120例气虚心瘀型慢性稳定型心绞痛患者,按1:1随机接受冠心静胶囊或安慰剂治疗8周,联合常规治疗。主要结局为运动耐量试验总运动时间变化和心绞痛症状积分变化,旨在评估冠心静胶囊的临床有效性和安全性。
要点
- 冠心静胶囊源自经典方血府逐瘀汤,基础与临床研究提示可缓解心绞痛症状。
- 采用中央随机系统1:1分配,安慰剂对照,双盲设计,治疗8周。
- 主要结局为运动耐量试验总运动时间及心绞痛症状积分变化。
核心结论
- 本研究旨在评估冠心静胶囊较安慰剂治疗慢性稳定型心绞痛(气虚心瘀证)的临床有效性和安全性。
研究设计与样本
- 多中心、盲法、随机对照试验,计划纳入120例慢性稳定型心绞痛(气虚心瘀证)患者。
- 采用中央随机系统按1:1随机分为冠心静胶囊组或安慰剂组,治疗8周,联合常规治疗。
- 设2周导入期,合格患者接受冠心静胶囊或安慰剂每次4粒、每日三次,共8周。
关键数值与推荐
- 主要结局包括运动耐量试验总运动时间变化和心绞痛症状积分变化。
- 次要结局包括最大估计做功量变化、ST段压低或抬高1 mm时间变化、运动耐量试验中心绞痛发作时间变化、中医证候总积分变化及广泛性焦虑障碍7项评估总积分变化(基线至第8周)。
- 所有运动耐量试验采用标准Bruce多级运动试验方案,全程监测不良事件。
临床怎么用
- 该研究结果将为冠心静胶囊应用于稳定型心绞痛治疗提供临床证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stable angina is a common cardiovascular disease with high mortality and a poor prognosis. Although there are various interventions against stable angina, none are able to significantly reduce the mortality rate. Guanxinjing capsule (GXJ) is made from the classical Chinese prescription Xuefuzhuyutang (). Both basic research and clinical studies have shown that GXJ can relieve the symptoms of angina, but currently, the effects of GXJ lack high-quality clinical evidence. The aim of this study was to evaluate the clinical effectiveness and safety of GXJ compared with placebo. METHODS/DESIGN: This multicentre, blinded, randomized trial will be conducted with a total of 120 participants diagnosed with chronic stable angina (Qi deficiency and blood stasis syndrome). Using a central randomization system, participants will be randomized (1:1) into groups receiving either GXJ or placebo for 8 weeks. After a 2-week run-in period, eligible patients will receive either GXJ or placebo (4 pills, three times daily) for 8 weeks in addition to conventional treatment. The primary outcomes include changes in the total exercise time on exercise tolerance tests and changes in the integral scores of angina symptoms. The secondary outcome measures include changes in the maximal estimated workload, changes in time to a 1 mm ST-segment depression or raise, changes in the time to onset of angina during exercise tolerance testing, changes in the total score of traditional Chinese medicine syndrome, and changes in the total score of the Generalized Anxiety Disorder 7-item assessment between baseline and week 8. Other outcome measures will also be assessed. All exercise tolerance tests use a standard Bruce multistage exercise test protocol. Adverse events will be monitored throughout the trial. DISCUSSION: This study will investigate whether GXJ can alleviate clinical symptoms, increase the angina-free walking time, and improve quality of life in patients with chronic stable angina (Qi deficiency and blood stasis syndrome). The results of this study will provide clinical evidence for the application of GXJ to the treatment of stable angina. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800014258 . Registered on 2 January 2018.
引用
- Tian Y, Zhang J, Zhao Y, et al. Guanxinjing capsule in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30342551. doi:10.1186/s13063-018-2950-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。